Insmed Incorporated Revenue and Competitors
Estimated Revenue & Valuation
- Insmed Incorporated's estimated annual revenue is currently $173.8M per year.
- Insmed Incorporated received $437.3M in venture funding in January 2018.
- Insmed Incorporated's estimated revenue per employee is $200,867
- Insmed Incorporated's current valuation is $2.8B. (January 2022)
Employee Data
- Insmed Incorporated has 865 Employees.
- Insmed Incorporated grew their employee count by 29% last year.
Insmed Incorporated Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $10.9M | 70 | 0% | N/A | N/A |
#2 | $0.9M | 6 | -14% | N/A | N/A |
#3 | $11.9M | 77 | -6% | N/A | N/A |
#4 | $106.8M | 492 | 23% | N/A | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $0.9M | 6 | 200% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1461 | 18% | $568M | N/A |
#9 | $2.5M | 16 | 0% | N/A | N/A |
#10 | $4.5M | 29 | 7% | N/A | N/A |
What Is Insmed Incorporated?
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. Headquartered in Bridgewater, NJ, we are a rapidly growing company with offices in seven countries.
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
865
Number of Employees
$173.8M
Revenue (est)
29%
Employee Growth %
$2.8B
Valuation
N/A
Accelerator
Insmed Incorporated News
Goldman Sachs Group Inc. now owns 463,326 shares of the biopharmaceutical company's stock valued at $12,621,000 after purchasing an additional...
Brokerages expect Insmed Incorporated (NASDAQ:INSM Get Rating) to announce sales of $53.63 million for the current quarter,...
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.
BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a bu ...
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three program ...
Other Companies in Bridgewater
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $421.5M | 907 | 0% | $200M |
#2 | $254.5M | 1010 | N/A | N/A |
#3 | $300M | 1316 | 26% | N/A |
#4 | $454.7M | 1414 | -6% | $1.2B |
#5 | $276.2M | 1771 | -2% | $68M |
Insmed Incorporated Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-07-14 | $12.0M | Private Placement | Wells Fargo Securities | Article |
| 2005-03-16 | $35.0M | Undisclosed | Multiple | Article |
| 2007-05-07 | $18.2M | Undisclosed | CE Unterberg Towbin | Article |
| 2012-10-01 | $26.0M | Undisclosed | Article | |
| 2013-07-18 | $62.4M | Undisclosed | Leerink Swann LLC | Article |
| 2014-08-13 | $80.0M | Undisclosed | Article | |
| 2015-04-01 | $194.0M | Undisclosed | Article | |
| 2015-04-07 | $223.0M | Undisclosed | Citigroup | Article |
| 2017-09-08 | $402.5M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-24 | $300.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
| 2018-01-25 | $437.3M | Undisclosed | Goldman Sachs & Co. LLC | Article |